These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

326 related items for PubMed ID: 33533931

  • 1. Association of Rituximab Use With Adverse Events in Children, Adolescents, and Young Adults.
    McAtee CL, Lubega J, Underbrink K, Curry K, Msaouel P, Barrow M, Muscal E, Lotze T, Srivaths P, Forbes LR, Allen C, Bernhardt MB.
    JAMA Netw Open; 2021 Feb 01; 4(2):e2036321. PubMed ID: 33533931
    [Abstract] [Full Text] [Related]

  • 2. Serious safety events in rituximab-treated multiple sclerosis and related disorders.
    Vollmer BL, Wallach AI, Corboy JR, Dubovskaya K, Alvarez E, Kister I.
    Ann Clin Transl Neurol; 2020 Sep 01; 7(9):1477-1487. PubMed ID: 32767531
    [Abstract] [Full Text] [Related]

  • 3. Predicting Severe Infection and Effects of Hypogammaglobulinemia During Therapy With Rituximab in Rheumatic and Musculoskeletal Diseases.
    Md Yusof MY, Vital EM, McElvenny DM, Hensor EMA, Das S, Dass S, Rawstron AC, Buch MH, Emery P, Savic S.
    Arthritis Rheumatol; 2019 Nov 01; 71(11):1812-1823. PubMed ID: 31131994
    [Abstract] [Full Text] [Related]

  • 4. Rituximab therapy has a rapid and durable response for refractory cytopenia in childhood-onset systemic lupus erythematosus.
    Olfat M, Silverman ED, Levy DM.
    Lupus; 2015 Aug 01; 24(9):966-72. PubMed ID: 25804672
    [Abstract] [Full Text] [Related]

  • 5. Late-onset adverse events after a single dose of rituximab in children with complicated steroid-dependent nephrotic syndrome.
    Fujinaga S, Ozawa K, Sakuraya K, Yamada A, Shimizu T.
    Clin Nephrol; 2016 Jun 01; 85(6):340-5. PubMed ID: 27125626
    [Abstract] [Full Text] [Related]

  • 6. Long-term outcomes after early treatment with rituximab for Japanese children with cyclosporine- and steroid-resistant nephrotic syndrome.
    Fujinaga S, Nishino T, Umeda C, Tomii Y, Watanabe Y, Sakuraya K.
    Pediatr Nephrol; 2019 Feb 01; 34(2):353-357. PubMed ID: 30426219
    [Abstract] [Full Text] [Related]

  • 7. Predictors of hospitalization due to infection in rituximab-treated MS patients.
    Karlowicz JR, Klakegg M, Aarseth JH, Bø L, Myhr KM, Torgauten HM, Torkildsen Ø, Wergeland S.
    Mult Scler Relat Disord; 2023 Mar 01; 71():104556. PubMed ID: 36842313
    [Abstract] [Full Text] [Related]

  • 8. [Rituximab therapy for severe pediatric systemic lupus erythematosus].
    Su GX, Wu FQ, Wang F, Zhou ZX, Huang XL, Lu J.
    Zhonghua Er Ke Za Zhi; 2012 Sep 01; 50(9):697-704. PubMed ID: 23158822
    [Abstract] [Full Text] [Related]

  • 9. Rituximab-induced hypogammaglobulinemia and infection risk in pediatric patients.
    Labrosse R, Barmettler S, Derfalvi B, Blincoe A, Cros G, Lacombe-Barrios J, Barsalou J, Yang N, Alrumayyan N, Sinclair J, Ong MS, Camargo CA, Walter J, Haddad E.
    J Allergy Clin Immunol; 2021 Aug 01; 148(2):523-532.e8. PubMed ID: 33862010
    [Abstract] [Full Text] [Related]

  • 10. The indications, efficacy and adverse events of rituximab in a large cohort of patients with juvenile-onset SLE.
    Watson L, Beresford MW, Maynes C, Pilkington C, Marks SD, Glackin Y, Tullus K.
    Lupus; 2015 Jan 01; 24(1):10-7. PubMed ID: 25117653
    [Abstract] [Full Text] [Related]

  • 11. Rituximab-associated hypogammaglobulinemia: incidence, predictors and outcomes in patients with multi-system autoimmune disease.
    Roberts DM, Jones RB, Smith RM, Alberici F, Kumaratne DS, Burns S, Jayne DR.
    J Autoimmun; 2015 Feb 01; 57():60-5. PubMed ID: 25556904
    [Abstract] [Full Text] [Related]

  • 12. Long-Term Efficacy and Safety of Repeated Rituximab to Maintain Remission in Idiopathic Childhood Nephrotic Syndrome: An International Study.
    Chan EY, Yu ELM, Angeletti A, Arslan Z, Basu B, Boyer O, Chan CY, Colucci M, Dorval G, Dossier C, Drovandi S, Ghiggeri GM, Gipson DS, Hamada R, Hogan J, Ishikura K, Kamei K, Kemper MJ, Ma AL, Parekh RS, Radhakrishnan S, Saini P, Shen Q, Sinha R, Subun C, Teo S, Vivarelli M, Webb H, Xu H, Yap HK, Tullus K.
    J Am Soc Nephrol; 2022 Jun 01; 33(6):1193-1207. PubMed ID: 35354600
    [Abstract] [Full Text] [Related]

  • 13. Adverse events linked with the use of chimeric and humanized anti-CD20 antibodies in children with idiopathic nephrotic syndrome.
    Bonanni A, Calatroni M, D'Alessandro M, Signa S, Bertelli E, Cioni M, Di Marco E, Biassoni R, Caridi G, Ingrasciotta G, Bertelli R, Di Donato A, Bruschi M, Canepa A, Piaggio G, Ravani P, Ghiggeri GM.
    Br J Clin Pharmacol; 2018 Jun 01; 84(6):1238-1249. PubMed ID: 29436729
    [Abstract] [Full Text] [Related]

  • 14. Human or Chimeric Monoclonal Anti-CD20 Antibodies for Children with Nephrotic Syndrome: A Superiority Randomized Trial.
    Ravani P, Colucci M, Bruschi M, Vivarelli M, Cioni M, DiDonato A, Cravedi P, Lugani F, Antonini F, Prunotto M, Emma F, Angeletti A, Ghiggeri GM.
    J Am Soc Nephrol; 2021 Oct 01; 32(10):2652-2663. PubMed ID: 34544820
    [Abstract] [Full Text] [Related]

  • 15. Immunoglobulin G replacement for the treatment of infective complications of rituximab-associated hypogammaglobulinemia in autoimmune disease: a case series.
    Roberts DM, Jones RB, Smith RM, Alberici F, Kumaratne DS, Burns S, Jayne DR.
    J Autoimmun; 2015 Feb 01; 57():24-9. PubMed ID: 25586449
    [Abstract] [Full Text] [Related]

  • 16. Incidence, Clinical Features, and Outcomes of Late-Onset Neutropenia From Rituximab for Autoimmune Disease.
    Zonozi R, Wallace ZS, Laliberte K, Huizenga NR, Rosenthal JM, Rhee EP, Cortazar FB, Niles JL.
    Arthritis Rheumatol; 2021 Feb 01; 73(2):347-354. PubMed ID: 32892495
    [Abstract] [Full Text] [Related]

  • 17. Association of Immunoglobulin Levels, Infectious Risk, and Mortality With Rituximab and Hypogammaglobulinemia.
    Barmettler S, Ong MS, Farmer JR, Choi H, Walter J.
    JAMA Netw Open; 2018 Nov 02; 1(7):e184169. PubMed ID: 30646343
    [Abstract] [Full Text] [Related]

  • 18. Rituximab Associated Hypogammaglobulinemia in Autoimmune Disease.
    Tieu J, Smith RM, Gopaluni S, Kumararatne DS, McClure M, Manson A, Houghton S, Jayne DRW.
    Front Immunol; 2021 Nov 02; 12():671503. PubMed ID: 34054846
    [Abstract] [Full Text] [Related]

  • 19. The effect of rituximab therapy on immunoglobulin levels in patients with multisystem autoimmune disease.
    Marco H, Smith RM, Jones RB, Guerry MJ, Catapano F, Burns S, Chaudhry AN, Smith KG, Jayne DR.
    BMC Musculoskelet Disord; 2014 May 25; 15():178. PubMed ID: 24884562
    [Abstract] [Full Text] [Related]

  • 20. Efficacy of standard dose rituximab for refractory idiopathic thrombocytopenic purpura in children.
    Dai WJ, Zhang RR, Yang XC, Yuan YF.
    Eur Rev Med Pharmacol Sci; 2015 Jul 25; 19(13):2379-83. PubMed ID: 26214772
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.